On July 10, 2025 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, reported that its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide") will be showcasing two presentations at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, in Baltimore, MD (Press release, Plus Therapeutics, JUL 10, 2025, View Source [SID1234654330]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CNSide data highlights its ability to quantify tumor cells and deliver actionable insights," said Michael Rosol, Ph.D., Plus Therapeutics’ Chief Development Officer. "The diagnostic assay is an exciting advancement for enhancing CNS metastases management and driving therapies like REYOBIQ in our ReSPECT-LM dose optimization trial."

Presentations:

Title CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker Assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease (BIOM-04), (FORESEE Study, NCT05414123)

Presenter
Priya Kumthekar, M.D.

Date/Time Thursday, August 14, 2025, 7:15 – 9:00 p.m. ET

Location Grand Ballroom VI

Title The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the LMD Tumor, (BIOM-03)

Presenter
Priya Kumthekar, M.D.

Date/Time Friday, August 15, 2025, 3:25 – 4:50 p.m. ET

Location Grand Ballroom I-V